This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
A phase 3 study of tiragolumab plus atezolizumab in patients with PD-L1–high NSCLC shows numerical survival improvements but fails to meet statistical endpoints.
Medscape Medical News